Cargando…

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma

Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gairing, Simon Johannes, Thol, Felix, Müller, Lukas, Hahn, Felix, Thomaidis, Thomas, Czauderna, Carolin, Bartsch, Fabian, Pitton, Michael Bernhard, Marquardt, Jens Uwe, Wörns, Marcus-Alexander, Galle, Peter Robert, Moehler, Markus, Weinmann, Arndt, Kloeckner, Roman, Foerster, Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235389/
https://www.ncbi.nlm.nih.gov/pubmed/34205670
http://dx.doi.org/10.3390/jcm10122732
_version_ 1783714306145124352
author Gairing, Simon Johannes
Thol, Felix
Müller, Lukas
Hahn, Felix
Thomaidis, Thomas
Czauderna, Carolin
Bartsch, Fabian
Pitton, Michael Bernhard
Marquardt, Jens Uwe
Wörns, Marcus-Alexander
Galle, Peter Robert
Moehler, Markus
Weinmann, Arndt
Kloeckner, Roman
Foerster, Friedrich
author_facet Gairing, Simon Johannes
Thol, Felix
Müller, Lukas
Hahn, Felix
Thomaidis, Thomas
Czauderna, Carolin
Bartsch, Fabian
Pitton, Michael Bernhard
Marquardt, Jens Uwe
Wörns, Marcus-Alexander
Galle, Peter Robert
Moehler, Markus
Weinmann, Arndt
Kloeckner, Roman
Foerster, Friedrich
author_sort Gairing, Simon Johannes
collection PubMed
description Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of patients treated with TACE and pCTX in unresectable iCCA at our tertiary care center. A group of 14 patients was treated with both pCTX and TACE. The non-randomized control group of 59 patients received pCTX alone. Patients received a median of two pCTX lines in both groups. Those treated with TACE underwent a median number of 3.5 sessions. Median OS from the time of unresectability was 26.2 months in the pCTX + TACE group versus 13.1 months in the pCTX group (p = 0.008). Controlling for albumin, bilirubin, ECOG (Eastern Cooperative Oncology Group) performance status, and UICC (Union for International Cancer Control) stage, the addition of TACE still conferred an OS benefit of 12.95 months (p = 0.014). A propensity score matching analysis yielded an OS benefit of 14 months from the time of unresectability for the pCTX + TACE group (p = 0.020). The addition of TACE to pCTX may provide an OS benefit for patients with unresectable iCCA. Thus, patients with liver-dominant iCCA undergoing standard-of-care pCTX should be considered for additional treatment with TACE.
format Online
Article
Text
id pubmed-8235389
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82353892021-06-27 The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma Gairing, Simon Johannes Thol, Felix Müller, Lukas Hahn, Felix Thomaidis, Thomas Czauderna, Carolin Bartsch, Fabian Pitton, Michael Bernhard Marquardt, Jens Uwe Wörns, Marcus-Alexander Galle, Peter Robert Moehler, Markus Weinmann, Arndt Kloeckner, Roman Foerster, Friedrich J Clin Med Article Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of patients treated with TACE and pCTX in unresectable iCCA at our tertiary care center. A group of 14 patients was treated with both pCTX and TACE. The non-randomized control group of 59 patients received pCTX alone. Patients received a median of two pCTX lines in both groups. Those treated with TACE underwent a median number of 3.5 sessions. Median OS from the time of unresectability was 26.2 months in the pCTX + TACE group versus 13.1 months in the pCTX group (p = 0.008). Controlling for albumin, bilirubin, ECOG (Eastern Cooperative Oncology Group) performance status, and UICC (Union for International Cancer Control) stage, the addition of TACE still conferred an OS benefit of 12.95 months (p = 0.014). A propensity score matching analysis yielded an OS benefit of 14 months from the time of unresectability for the pCTX + TACE group (p = 0.020). The addition of TACE to pCTX may provide an OS benefit for patients with unresectable iCCA. Thus, patients with liver-dominant iCCA undergoing standard-of-care pCTX should be considered for additional treatment with TACE. MDPI 2021-06-21 /pmc/articles/PMC8235389/ /pubmed/34205670 http://dx.doi.org/10.3390/jcm10122732 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gairing, Simon Johannes
Thol, Felix
Müller, Lukas
Hahn, Felix
Thomaidis, Thomas
Czauderna, Carolin
Bartsch, Fabian
Pitton, Michael Bernhard
Marquardt, Jens Uwe
Wörns, Marcus-Alexander
Galle, Peter Robert
Moehler, Markus
Weinmann, Arndt
Kloeckner, Roman
Foerster, Friedrich
The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
title The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
title_full The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
title_fullStr The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
title_full_unstemmed The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
title_short The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
title_sort addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235389/
https://www.ncbi.nlm.nih.gov/pubmed/34205670
http://dx.doi.org/10.3390/jcm10122732
work_keys_str_mv AT gairingsimonjohannes theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT tholfelix theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT mullerlukas theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT hahnfelix theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT thomaidisthomas theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT czaudernacarolin theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT bartschfabian theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT pittonmichaelbernhard theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT marquardtjensuwe theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT wornsmarcusalexander theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT gallepeterrobert theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT moehlermarkus theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT weinmannarndt theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT kloecknerroman theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT foersterfriedrich theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT gairingsimonjohannes additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT tholfelix additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT mullerlukas additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT hahnfelix additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT thomaidisthomas additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT czaudernacarolin additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT bartschfabian additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT pittonmichaelbernhard additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT marquardtjensuwe additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT wornsmarcusalexander additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT gallepeterrobert additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT moehlermarkus additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT weinmannarndt additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT kloecknerroman additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma
AT foersterfriedrich additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma